Mainstay Medical has secured $125 million in equity financing to enhance commercial growth and clinical evidence for its ReActiv8® Restorative Neurostimulation™ System, aimed at treating chronic low back pain.
Information on the Target
Mainstay Medical Holdings plc specializes in the development and commercialization of innovative medical devices. Their flagship product, the ReActiv8® Restorative Neurostimulation™ System, is designed to address intractable chronic low back pain (CLBP) resulting from multifidus muscle dysfunction. This condition affects adults who have not found relief through conventional treatments, including pain medications and physical therapy, and who are not suitable candidates for spine surgery.
The ReActiv8 system is currently approved and available in key markets, including the European Economic Area, Australia, the United Kingdom, and the United States. This implantable device represents a breakthrough in the treatment of CLBP, offering a unique therapeutic approach that aims to restore function and alleviate pain.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview
The medical device industry, especially in the field of pain management, is witnessing significant advancements, particularly in Europe and the U.S. Chronic low back pain is a prevalent issue, affecting millions worldwide and presenti
Similar Deals
Claret Capital Partners → Deciphex
2025
BGF → Avoca Clinic
2023
Unmind → Frankie Health
2023
Beechbrook Capital → Bio-Medical Research Limited
2019
BDO Development Capital Fund → Lifes2good Group
2015
BDO Development Capital Fund → Perigord
Gilde Healthcare, Viking Global Investors
invested in
Mainstay Medical Holdings plc
in 2024
in a Growth Equity & Expansion Capital deal
Disclosed details
Transaction Size: $125M